Artal Group S.A. Biomarin Pharmaceutical Inc Call Options Transaction History

Artal Group S.A.

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2021 Aug 13, 2021	SELL	$75.51 - $84.79 $11.3 Million - $12.7 Million	-150,000 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$71.87 - $131.03 $10.8 Million - $19.7 Million	150,000 New	150,000 $11.4 Million
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $15.9 Million - $24.8 Million	-200,000 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$71.37 - $96.85 $7.14 Million - $9.69 Million	100,000 Added 100.0%	200,000 $16.9 Million
Q4 2019 Feb 13, 2020	BUY	$64.27 - $86.37 $6.43 Million - $8.64 Million	100,000 New	100,000 $8.46 Million
Q1 2019 May 10, 2019	SELL	$84.2 - $98.62 $16.8 Million - $19.7 Million	-200,000 Closed	0 $0
Q1 2018 May 10, 2018	BUY	$77.67 - $92.63 $7.77 Million - $9.26 Million	100,000 Added 100.0%	200,000 $16.2 Million
Q3 2017 Nov 08, 2017	BUY	$80.6 - $94.95 $8.06 Million - $9.5 Million	100,000	100,000 $9.31 Million

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.